DHEA-S Interpretation by Decade of Life

What Is DHEA-S and Why Does It Decline?

DHEA-S (dehydroepiandrosterone sulfate) is the sulfated, water-soluble storage form of DHEA produced almost entirely by the adrenal zona reticularis. Its long serum half-life of 7 to 10 hours makes it a far more stable biomarker than unconjugated DHEA, which fluctuates throughout the day. The sulfate group is added and removed by sulfotransferases and steroid sulfatase, creating a circulating reservoir that peripheral tissues convert to androgens and estrogens on demand.

The decline is not caused by disease in most people. It reflects a programmed reduction in zona reticularis cell mass and 17,20-lyase activity. This age-related fall is sometimes called adrenopause to distinguish it from gonadal menopause or andropause, though the term is informal.

Why Serum DHEA-S Rather Than DHEA?

DHEA itself shows a marked diurnal rhythm, peaking in the early morning and dropping 20 to 30 percent by afternoon. DHEA-S concentration varies less than 10 percent across the day, which is why clinical laboratories measure the sulfated form. A fasting morning draw is still preferred for consistency, but a strict 8 a.m. Protocol is less critical than it is for cortisol or total testosterone.

Adrenal vs. Gonadal Contribution

In pre-menopausal women, the ovaries contribute a small fraction of circulating DHEA. After menopause, the adrenal gland becomes the dominant source for both DHEA-S and its downstream estrogens. In men, testicular DHEA output is minor. This means DHEA-S is a cleaner adrenal-specific marker in men than in pre-menopausal women, though the clinical difference is modest.

Reference Ranges by Decade: What the Data Actually Show

Published reference intervals vary between assay platforms, but the decade-by-decade pattern is highly reproducible across large epidemiological studies. The NHANES III data and the Rochester Epidemiology Project both document the characteristic inverted-U shape with peak in the third decade and progressive decline thereafter [1].

The table below summarizes commonly cited age- and sex-specific ranges. These are 2.5th-to-97.5th percentile intervals from laboratory method sheets calibrated to LC-MS/MS, the current gold-standard assay.

| Age Decade | Men (µg/dL) | Women (µg/dL) | |---|---|---| | 18 to 29 | 280 to 640 | 145 to 395 | | 30 to 39 | 215 to 540 | 110 to 370 | | 40 to 49 | 160 to 450 | 85 to 310 | | 50 to 59 | 115 to 370 | 65 to 240 | | 60 to 69 | 75 to 290 | 40 to 190 | | 70 to 79 | 40 to 200 | 20 to 130 | | 80+ | 20 to 150 | 10 to 90 |

Ranges are approximate and platform-dependent. Always compare results against the reporting laboratory's own reference interval.

Interpreting a Result That Sits at the Low End of Its Decade Range

A result that falls within the statistical reference interval is not automatically "optimal." Longevity-medicine clinicians frequently target the upper third of the age-matched range, roughly the 50th-to-75th percentile for chronological age, because observational data link higher-decade DHEA-S with better physical performance and lower cardiovascular risk [2]. There is no randomized-controlled-trial evidence proving that correcting a low-normal DHEA-S to the upper tercile improves hard clinical outcomes.

Interpreting a Result Above the Decade Ceiling

A DHEA-S that exceeds the 97.5th percentile for age warrants investigation. In women of reproductive age, polycystic ovary syndrome (PCOS) and congenital adrenal hyperplasia (CAH) are the most common explanations. In post-menopausal women and in men of any age, an adrenal adenoma secreting DHEA-S must be excluded. Imaging with adrenal CT or MRI is appropriate when DHEA-S exceeds 700 µg/dL regardless of sex or age [3].

Decade-by-Decade Clinical Significance

Ages 18 to 29: Establishing a Personal Baseline

DHEA-S is highest in this decade. A result below 200 µg/dL in a man or below 100 µg/dL in a woman aged 18 to 29 should prompt evaluation for primary adrenal insufficiency, hypopituitarism, or exogenous glucocorticoid use (which suppresses ACTH and, secondarily, DHEA-S production). The 2016 Endocrine Society clinical practice guideline on adrenal insufficiency lists low DHEA-S as one of several supporting biomarkers in ambiguous cases [4].

Getting a baseline DHEA-S in the mid-20s gives clinicians a personal reference point for tracking the rate of decline over subsequent decades, which is more informative than any single cross-sectional reading.

Ages 30 to 39: The Slope Becomes Clinically Relevant

Decline accelerates modestly in the fourth decade. Chronic psychological stress raises cortisol and suppresses DHEA-S, widening the cortisol-to-DHEA-S ratio. Several studies have used this ratio as a proxy for allostatic load [5]. A ratio above 20 (both measured in µg/dL, drawn in the morning fasting state) has been proposed as a threshold for clinical concern, though this cutoff has not been validated in prospective outcome trials.

Ages 40 to 49: Perimenopause Compounds the Drop in Women

Women entering perimenopause lose both ovarian estrogen and a modest ovarian DHEA contribution simultaneously. DHEA-S that was mid-range at age 38 may fall to the lower quartile by age 47 without any adrenal pathology. Clinicians interpreting DHEA-S in perimenopausal women should account for this and avoid over-medicating a physiological transition.

In men, the fourth decade is often when symptom-driven testing begins. Low DHEA-S in this group frequently coexists with low total testosterone. Treating only testosterone without evaluating the broader adrenal androgen picture is incomplete.

Ages 50 to 59: Adrenopause Becomes Clinically Apparent

By the sixth decade, the average person has lost 40 to 50 percent of their peak DHEA-S. Symptoms attributed to low DHEA-S overlap heavily with those of hypogonadism and menopause: fatigue, decreased libido, reduced skin moisture, and impaired sense of well-being. Attributing symptoms to DHEA-S specifically requires ruling out thyroid dysfunction, iron deficiency, depression, and sleep apnea before supplementation is considered.

The DHEAge study (Baulieu et al., 2000; N=280, ages 60 to 79) randomized participants to DHEA 50 mg/day or placebo for 12 months and found significant improvements in bone mineral density, skin hydration, and libido, with the strongest effects in women over 70 and men over 70 [6]. Participants in their 50s showed smaller and less consistent gains, suggesting the intervention may be more meaningful when levels have fallen to near-nadir concentrations.

Ages 60 to 69: Functional Decline and Fall Risk

Low DHEA-S in the seventh decade correlates with reduced muscle mass and grip strength in cross-sectional analyses. The InCHIANTI study (N=1,155, ages 65 and older) found that DHEA-S in the lowest quartile was associated with a 40 percent higher odds of slow walking speed, a validated predictor of future disability [7]. Causal inference is limited by the observational design, but the association is biologically plausible given DHEA-S's role as a precursor to testosterone and estradiol in skeletal muscle.

Ages 70 and Beyond: Cardiovascular and Cognitive Associations

The most provocative longevity data come from the oldest age groups. In the MrOS study (N=2,639 men, mean age 73), men in the lowest DHEA-S quartile had a 67 percent higher risk of cardiovascular mortality over 5 years compared to men in the highest quartile, after adjusting for established cardiovascular risk factors [8]. Whether DHEA-S is a causal driver or a marker of overall adrenocortical reserve remains unsettled.

Cognitive data are more mixed. A Cochrane systematic review of DHEA supplementation (2006, updated assessments through 2020) found no consistent benefit for cognition in older adults without pre-existing cognitive impairment [9].

Optimal DHEA-S: Population Percentile vs. Functional Target

"Optimal" means different things depending on the clinical framework applied. Three approaches dominate the literature.

The Population-Percentile Approach

Match the patient's result to the median for their sex and decade. A result at the 50th percentile is "normal." This is the standard used by most clinical laboratories and endorsed implicitly by the Endocrine Society, which recommends replacement therapy only when DHEA-S falls below the reference interval for the patient's age and sex in the context of proven adrenal insufficiency [4].

The Biologically Youthful Percentile Approach

Some longevity medicine practitioners target DHEA-S at the 50th-to-75th percentile of a younger reference decade (typically 10 to 20 years younger than the patient's chronological age), on the basis that most age-related DHEA-S decline is not pathological but may still be modifiable and clinically meaningful. This approach is not supported by randomized trial evidence showing improved mortality or morbidity endpoints. It is a clinical hypothesis, not a guideline recommendation. Clinicians using this framework should document their reasoning explicitly in the chart.

The Symptom-Correlation Approach

A third strategy anchors dosing decisions to symptom burden rather than a specific number. Under this model, a 62-year-old woman with DHEA-S of 45 µg/dL (technically within her decade range but at the 10th percentile) who reports low libido, fatigue, and skin changes may be offered a low-dose DHEA trial (typically 10 to 25 mg/day in women, 25 to 50 mg/day in men) with a plan to recheck DHEA-S, free testosterone, and estradiol in 6 to 8 weeks. This approach requires monitoring for androgenic side effects: acne, increased facial hair in women, and oiliness.

Causes of Abnormally Low DHEA-S at Any Age

Not every low reading is adrenopause. Clinicians should systematically exclude the following before attributing a low DHEA-S to aging alone.

Exogenous Glucocorticoid Suppression

Prednisone, dexamethasone, budesonide, and even high-dose inhaled corticosteroids suppress hypothalamic-pituitary-adrenal (HPA) axis activity. Patients on 7.5 mg/day or more of prednisone-equivalent for more than 3 weeks commonly have DHEA-S values in the geriatric range regardless of their chronological age. This is the most common drug-induced cause of low DHEA-S [10].

Primary Adrenal Insufficiency (Addison's Disease)

In primary adrenal insufficiency, cortisol, aldosterone, and DHEA-S are all low. The diagnosis rests on a morning cortisol below 3 µg/dL and a suboptimal ACTH stimulation test response, not on DHEA-S alone. The Endocrine Society guideline advises against using DHEA-S as a stand-alone screening test for adrenal insufficiency [4].

Hypopituitarism

Secondary adrenal insufficiency (low ACTH from a pituitary or hypothalamic lesion) reduces DHEA-S along with cortisol. An isolated DHEA-S that is markedly below the decade nadir in a patient with headache, vision changes, or hypogonadism should prompt pituitary MRI.

Medications Beyond Steroids

Metformin, statins, and oral contraceptives containing high-dose progestins can each lower DHEA-S by 10 to 30 percent, though the clinical significance of these reductions is debated [11]. Document current medications before interpreting the result.

Causes of Elevated DHEA-S

A result above the decade ceiling is not a longevity advantage. It requires structured investigation.

PCOS and Functional Adrenal Hyperandrogenism

In women aged 18 to 44, DHEA-S of 350 to 500 µg/dL with clinical hyperandrogenism (hirsutism, acne, oligomenorrhea) is most often PCOS with an adrenal androgenic component. DHEA-S rarely exceeds 700 µg/dL in PCOS. Values above that threshold increase the prior probability of an adrenal adenoma.

Classic and Non-Classic CAH

21-hydroxylase deficiency, the most common form of CAH, can present in adulthood as late-onset adrenal hyperandrogenism. The diagnostic test is a morning 17-hydroxyprogesterone level. If the basal level exceeds 200 ng/dL in an adult, an ACTH stimulation test is indicated per Endocrine Society guidelines [12].

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is rare (1 to 2 cases per million per year) but can produce extreme DHEA-S elevations, sometimes exceeding 1,000 µg/dL. Rapid-onset virilization in a woman or cushingoid features with a very high DHEA-S are red flags that warrant immediate imaging.

Testing Protocol and Ordering Considerations

Specimen Type and Timing

Order serum DHEA-S, not plasma DHEA-S. Most immunoassay and LC-MS/MS platforms are validated for serum. A morning fasting specimen (7 to 9 a.m.) is preferred. Unlike cortisol, DHEA-S does not require a strict timed collection, but morning is standard across the studies that generated the reference intervals above.

Assay Platform Matters

Immunoassay DHEA-S results can differ by 10 to 25 percent from LC-MS/MS results on the same sample. The Endocrine Society's 2010 testosterone measurement guidelines (which cover adrenal androgens by extension) recommend LC-MS/MS for clinical decisions where precise quantitation is required [13]. If a patient's result seems inconsistent with their symptoms, requesting LC-MS/MS confirmation at a reference laboratory is appropriate.

How Often to Recheck

For patients on DHEA replacement, recheck DHEA-S, free testosterone, and estradiol at 6 to 8 weeks after dose initiation or any dose change. Once stable, annual testing is sufficient. For patients not on replacement who simply want longitudinal tracking, annual or biennial testing is reasonable from age 40 onward.

DHEA Supplementation: Evidence Summary

Oral DHEA is available without a prescription in the United States as a dietary supplement. Prescription-grade DHEA is used in Europe and Canada. The regulatory status does not alter the pharmacokinetics: 50 mg oral micronized DHEA raises serum DHEA-S by approximately 200 to 300 µg/dL in older adults within 2 weeks [6].

What the Evidence Supports

The DHEAge trial (Baulieu et al., 2000; N=280) remains the largest placebo-controlled DHEA replacement trial in healthy older adults. Bone mineral density increased significantly at the femoral neck in women over 70 (P<0.05). Libido improved in both sexes, more markedly in women [6]. The trial was 12 months in duration and was not powered for fracture or cardiovascular outcomes.

The ECHO trial (Nair et al., 2006; NEJM; N=87, ages 60 to 88) tested DHEA 75 mg/day plus low-dose testosterone in older adults and found no significant effect on body composition, physical performance, or insulin sensitivity versus placebo over 2 years [14].

What the Evidence Does Not Support

DHEA supplementation has not been shown to reduce all-cause mortality, prevent cardiovascular events, or improve cognitive function in randomized controlled trials of healthy older adults. The Cochrane review on DHEA found insufficient evidence to recommend supplementation for age-related cognitive decline [9].

Dosing in Clinical Practice

For confirmed adrenal insufficiency, the Endocrine Society recommends DHEA 25 to 50 mg/day as adjunctive therapy in women with persistent fatigue and low well-being despite adequate glucocorticoid and mineralocorticoid replacement [4]. In men, the same guideline finds insufficient evidence for routine DHEA replacement even in adrenal insufficiency. Outside of adrenal insufficiency, DHEA use is off-label and should be framed to patients as a low-evidence intervention with real androgenic side-effect potential.